FREQUENTLYASKED QUESTIONS
About ERLEADA®
ERLEADA® is indicated for the treatment of patients with1:
- Metastatic castration-sensitive prostate cancer (mCSPC)
- Non-metastatic castration-resistant prostate cancer (nmCRPC)
Reference: 1. ERLEADA® [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc.
ERLEADA® is an androgen-receptor (AR) inhibitor that inhibits AR signaling at multiple sites of action1:
- Binds directly to the ligand-binding domain of the AR
- Inhibits AR nuclear translocation
- Inhibits DNA binding
- Impedes AR-mediated transcription
Reference: 1. ERLEADA® [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc.
- The recommended dose of ERLEADA® is 240 mg (four 60 mg tablets) administered orally once daily1
- Patients should also receive a GnRH analog concurrently or should have had a bilateral orchiectomy1
- If Grade 3 or greater adverse reactions, or other intolerable adverse reactions occur, withhold ERLEADA®. Consider permanent discontinuation of ERLEADA® for Grade 3 or 4 cerebrovascular and ischemic cardiovascular events. Permanently discontinue ERLEADA® for confirmed SCARs or for other Grade 4 skin reactions. For other adverse reactions, when symptoms improve to less than or equal to Grade 1 or original grade, resume ERLEADA® at the same dose or a reduced dose (180 mg or 120 mg), if warranted1
Find out more about dosing and administration
Reference: 1. ERLEADA® [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc.
